New data on ac immune's abeta and ptau clinical programs in alzheimer's disease to be presented at ctad 2021

Lausanne, switzerland, nov. 02, 2021 (globe newswire) -- ac immune sa (nasdaq: aciu), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases,  today announces that new data on its investigational alzheimer's disease (ad) candidates semorinemab, aci-35.030 and aci-24 will be featured in the scientific program of the clinical trials on alzheimer's disease (c-tad) conference, taking place virtually and in person in boston, on november 9-12, 2021.
ACIU Ratings Summary
ACIU Quant Ranking